drugset / Trial / NCT00343486
Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will test the effectiveness and safety of two doses of solabegron against placebo in reducing the symptoms of overactive bladder.
Timeline
- Start
- 2006-05
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Solabegron | Unknown | 50 mg | Oral |
| Subject | Solabegron | Unknown | 125 mg | Oral |